|
Sign In to gain access to subscriptions and/or personal tools.
|
New Therapies for Osteoporosis
Karly A. Hegge, PharmD, BCPS*,
Anisa S. Fornoff, PharmD,
Sheryl L. Gutierres, PharmD,
and
Sally L. Haack, PharmD
* To whom correspondence should be addressed. E-mail: karly.hegge{at}sdstate.edu.
 |
Abstract |
|---|
Osteoporosis is a growing health concern in the United States, with an enormous impact on morbidity and mortality. Despite published guidelines to aid clinicians in its management, several controversies remain. Many trials evaluate surrogate measures of bone strength rather than more clinically relevant outcomes, including fracture. Furthermore, the role of combination and sequential therapy remains unclear. Limited data are available regarding appropriate duration of therapy, management of osteoporosis in men, and treatment of glucocorticoid-induced osteoporosis. The develop-ment of unique therapeutic agents could potentially revolutionize the treatment of osteoporosis. Once yearly zoledronic acid may provide advantages over existing therapies. Because of limitations with existing selective estrogen receptor modulators, the search for agents with better efficacy and safety profiles has led to the development of several new medications within this class. Finally, denosumab, a monoclonal antibody to receptor activator for nuclear factor-kappa B ligand, also represents a novel therapeutic option for osteoporosis.
First published on October 21, 2008, doi:10.1177/0897190008322247
Journal of Pharmacy Practice 2009;22:53.
A more recent version of this article appeared on February 1, 2009
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
